Drug Approval | October 20, 2021
FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Second interchangeable biosimilar product approved by agency
Second interchangeable biosimilar product approved by agency
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
The BiCNU brand and generic market had U.S. sales of approximately US $ 19.4 million MAT for the most recent twelve months ending in August 2021, according to IQVIA Health
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
The drug is being developed at lab scale for the first-line of treatment of Covid-19
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
Subscribe To Our Newsletter & Stay Updated
